Next Generation Sequencing (NGS) Market Poised to Hit $42.25 Billion by 2033: Key Drivers Behind the Surge - Latest Study by Grand View Research, Inc.
SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology ...
This eBook explores next-generation sequencing (NGS) methods and their applications in neurological and cancer research, with key content from BioTechniques’ digital hub and Taylor & Francis journals, ...
News Medical on MSN
Enhancing the cancer-immunity cycle through innovative vaccines
Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward harnessing the immune system's intrinsic ability to combat ...
Precision medicine relies on biomarker testing to match therapies to specific cancers, yet many patients remain untested due ...
Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the launch of oncoReveal® Lymphoid, a ...
This study demonstrates that NGS-MSI is noninferior to IHC-MMR and can identify MSI-H tumors that IHC-MMR is unable to detect and conversely IHC-MMR can identify MMRd tumors that NGS-MSI misses. This ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, ...
Cancer charities also in attendance at the session, entitled ‘Closing the Gap: Bringing Cancer Genomic Testing to Scottish ...
The race for early cancer detection is one that physicians have been running for millennia. In one of humanity’s oldest surviving medical texts, the ancient Egyptian physician Imhotep described 46 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback